{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:31Z","timestamp":1790710171992,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T00:00:00Z","timestamp":1567900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hypersensitivity reactions (HSR) to biologic drugs (BD) may limit their use in children with rheumatic diseases. We aimed to analyze the incidence and clinical characteristics of immediate type I (IgE\/non\u2010IgE) hypersensitivity reactions to BD and the risk factors for these reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Children with rheumatic diseases using BD who were evaluated in the pediatric allergy department for possible drug hypersensitivity reaction (DHR) due to BD or any other drug were included in the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and twenty\u2010eight children (49.2% boys; 14.6\u00a0years [9.9\u201016.9\u00a0years] with juvenile idiopathic arthritis [58%], familial Mediterranean fever [14%], vasculitis [14%], and other diseases [14%]) had used eight different BD with 32\u00a0494 infusions\/injections. Fifteen patients were evaluated for DHR [injection\u2010site reactions [n\u00a0=\u00a04], adverse events [n\u00a0=\u00a02], drug hypersensitivity other than BD [n\u00a0=\u00a03], and immediate BD hypersensitivity [n\u00a0=\u00a06]). The incidence of immediate BD HSR was 4.7%, with a clinical presentation of anaphylaxis in 3.9% (tocilizumab [n\u00a0=\u00a03], rituximab [n\u00a0=\u00a02], positive skin test with culprit BD [n\u00a0=\u00a03]). Among patients with BD HSR, the median follow\u2010up was longer (84.5 vs 54\u00a0months, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.048), and renal (33.3% vs 4.1%, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.002), hematologic involvement (16.7% vs 0, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001), and active disease (83.3% vs 13.9%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) were more common. Logistic regression analysis revealed that renal involvement, more than 14 hospitalizations per lifetime, and more than two different BD used were associated with BD hypersensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The frequency of severe immediate HSR due to BD was shown to be 3.9% in children with rheumatic diseases. Children with active rheumatic disease and who have exposure to multiple BD should be monitored for BD HSR, particularly during intravenous BD infusions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pai.13114","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T18:19:03Z","timestamp":1565979543000},"page":"833-840","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-251X","authenticated-orcid":false,"given":"Ozge","family":"Soyer","sequence":"first","affiliation":[{"name":"Department of Pediatrics Division of Allergy Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcan","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelda","family":"Bilginer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi Deniz","family":"Batu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafize Emine","family":"Sonmez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Serap","family":"Ar\u0131c\u0131","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-913X","authenticated-orcid":false,"given":"\u00dcmit Murat","family":"\u015eahiner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Allergy Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4232-3396","authenticated-orcid":false,"given":"Bulent Enis","family":"Sekerel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Allergy Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3800"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092866"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2015.08.012"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.63"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2011.11.004"},{"issue":"1","key":"e_1_2_6_9_1","first-page":"129","article-title":"Hypersensitivity reactions during treatment with biological agents","volume":"34","author":"Puxeddu I","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-3900-z"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12350"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.009"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu181"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13142"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.07.012"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22110"},{"issue":"1","key":"e_1_2_6_19_1","first-page":"134","article-title":"Serious infusion\u2010related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data","volume":"57","author":"Salmon J\u2010H","year":"2018","journal-title":"Rheumatology"},{"issue":"213","key":"e_1_2_6_20_1","first-page":"e212","article-title":"Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review","volume":"187","author":"Mahmoud I","year":"2017","journal-title":"J Pediatr"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-016-3559-2"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.5.369"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2096-3"},{"issue":"4","key":"e_1_2_6_25_1","first-page":"493","article-title":"Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin\u20101 receptor antagonist (rhIL\u20101ra) and\/or its vehicle: possible clinical implications","volume":"125","author":"Bendele A","year":"1995","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.05.013"},{"issue":"10","key":"e_1_2_6_27_1","first-page":"1912","article-title":"Infusion\u2010related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number","volume":"31","author":"Wasserman MJ","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05784.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0081"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1952"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12915"}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpai.13114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.13114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pai.13114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.13114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T22:39:16Z","timestamp":1693694356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pai.13114"}},"subtitle":[],"editor":[{"given":"Marina","family":"Atanaskovic\u2010Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/pai.13114"],"URL":"https:\/\/doi.org\/10.1111\/pai.13114","archive":["Portico"],"relation":{},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,8]]},"assertion":[{"value":"2019-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}